Abstract: Helicases are promising antiviral drug targets because their enzymatic activities are essential for viral genome replication, transcription, and translation. Numerous potent inhibitors of helicases encoded by herpes simplex virus, severe acute respiratory syndrome coronavirus, hepatitis C virus, Japanese encephalitis virus, West Nile virus, and human papillomavirus have been recently reported in the scientific literature. Some inhibitors have also been shown to decrease viral replication in cell culture and animal models. This review discusses recent progress in understanding the structure and function of viral helicases to help clarify how these potential antiviral compounds function and to facilitate the design of better inhibitors. The above helicases and all related viral proteins are classified here based on their evolutionary and functional similarities, and the key mechanistic features of each group are noted. All helicases share a common motor function fueled by ATP hydrolysis, but differ in exactly how the motor moves the protein and its cargo on a nucleic acid chain. The helicase inhibitors discussed here influence rates of helicase-catalyzed DNA (or RNA) unwinding by preventing ATP hydrolysis, nucleic acid binding, nucleic acid release, or by disrupting the interaction of a helicase with a required cofactor.
INTRODUCTION
Viruses evolve rapidly to evade not only the human immune system but also antiviral drugs. Although it is sometimes possible to use only a single antiviral drug to control DNA viruses that proofread and repair their genomes, single agents are rarely effective for viruses that evolve more rapidly. The most successful method to control such a virus is to simultaneously target multiple loci with several agents. Such combination therapies successfully control human immunodeficiency virus (HIV) replication to delay the development of AIDS, and are presently the standard of care for HIV patients. Similar approaches could be used to combat other viruses, but the technique is limited because most present antiviral drugs function by inhibiting either viral proteases, which are needed to process viral proteins, or nucleic acid polymerases, which are required to copy the viral genome. Although a few other antiviral drugs function by blocking viral entry or by modulating the host immune system, more drug targets are clearly needed. This review focuses on the development of another critical protein synthesized by many viruses, an enzyme called helicase, as a potential antiviral drug target.
Helicases are motor proteins that use energy derived from ATP hydrolysis to separate nucleic acid strands. Such an activity is necessary at several points during genome replication. In viruses with duplex nucleic acid genomes, the double helix must be separated for copying. Conversely, viruses with single-stranded genomes must separate duplexes that form after genome replication. Helicases have also been shown to be required in transcription of viral mRNAs, *Address correspondence to this author at the Department of Biochemistry and Molecular Biology, New York Medical College, Valhalla, NY 10595, USA; Tel: 914-594-4190; Fax: 914-594-4058; E-mail: David_Frick@NYMC.edu translation, disruption of RNA-protein complexes, and packaging of nucleic acids into virions. Most importantly, their validity as antiviral drug targets was recently confirmed when compounds that inhibit a helicase encoded by herpes simplex virus (HSV) were shown to block viral replication and disease progression in animal models [1, 2] .
Most of the best-studied viral helicases are encoded by large DNA viruses or bacteriophage. In fact, some of the first helicases identified over two decades ago were purified from these organisms [3] [4] [5] . Similar proteins are encoded by several important human pathogens like HSV and human papillomavirus (HPV). About 10 years after the discovery of DNA helicases, similar proteins were found to be made by RNA viruses [6] . Most species of positive sense singlestranded RNA ((+)ssRNA) viruses encode a helicase, and several of these proteins have now been extensively studied. The most detailed structural and mechanistic studies have been performed using the RNA helicase encoded by hepatitis C virus (HCV). A few other helicases from pathogenic human RNA viruses have also been studied in detail including those from severe acute respiratory syndrome coronavirus (SARS-CoV), Dengue fever virus (DFV), Japanese encephalitis virus (JEV), and West Nile virus (WNV). Curiously, no retroviruses or negative sense single-stranded RNA ((-)ssRNA) viruses have been reported to encode the synthesis of a helicase. Since the members of these classes replicate in the nucleus, they might simply utilize helicases encoded by the host instead of their own proteins. Indeed, HIV replication has recently been shown to require the human DDX3 DEAD-box RNA helicase [7] . Large DNA viruses that invade the nucleus, like HSV, frequently bring with them a full complement of replication proteins, including at least one helicase. Viruses that replicate outside the nucleus almost always encode a helicase, without which they cannot survive.
Developing non-toxic helicase inhibitors is considerably more difficult than developing drugs designed to inhibit other viral enzymes. Problems arise from several areas. First, compared with proteases and polymerases, the mechanisms of the reactions catalyzed by helicases are still not as clearly understood. Second, the helicase ATP-binding site is conserved not only in all classes of helicases, but also in motor proteins, small GTPases, kinases, the AAA+ family (ATPases associated with various cellular activities), and even the mitochondrial ATP synthase (F 1 ATPase) (Fig. (1) ). Thus, compounds that inhibit helicases via their ATPbinding sites could be quite toxic. Third, the role of helicases in the viral lifecycle is still not well-defined. Although, in vitro all helicases are able to separate a nucleic acid strand from its complement, their movements could also rearrange secondary structures or dislodge nucleic acid binding proteins. Finally, the traditional assays measuring helicasecatalyzed unwinding are tedious, making inhibitor screening time-consuming. In the past few years, considerable progress has been made in the area of assay development (see reference [8] for a review) and it is now possible to identify potent helicase inhibitors using high throughput screening. The challenge now is to understand how these compounds interact with helicases so that they can be developed into actual drugs.
This review will summarize the various viral helicases that have been characterized to date, their evolutionary relationships, mechanisms of action, and any inhibitors that have been reported in the scientific literature. The helicase literature is rapidly expanding but fortunately the field is frequently reviewed, and the reader will be directed to relevant reviews in appropriate sections. It should also be noted at this point that Delagoutte & von Hippel have recently reviewed the entire helicase field in an extensive two-part review that is highly recommended [9, 10] .
VIRAL HELICASE CLASSIFICATION
The best way to understand the bewildering amount of viral helicase information is to realize that all helicases, from both viruses and cellular organisms, share many common properties. Understanding these features will provide the basis for understanding the mechanism of action of these complex enzymes. It should also be recognized that nature has used the basic building blocks shared by all helicases to manipulate nucleic acids in many different ways and for many different purposes. As a result, different helicase families have evolved that share little resemblance, at least superficially. Thus, to really understand viral helicases, one must understand the common properties shared by all helicases, and the distinctive properties that characterize the various Fig. (1) . Evolutionary relationship of viral helicases. All known viral helicases belong either to one of three helicase superfamilies or to the RecA/F 1 -ATPase superfamily. The five families of viral helicases from DNA viruses and three families of viral helicases from RNA viruses are highlighted with grey bars. Prototypes of each family are listed in parentheses. SF3 and DnaB-like helicases are fundamentally different from SF1 and SF2 helicases in that they contain only one RecA-like domain per subunit and must form rings and/or filaments to catalyze ATP hydrolysis. All helicases are in the ASCE subdivision of P-loop NTPases and share many basic features with the numerous other protein families listed. The diagram is based on information found in references [234, 235] .
helicase families. If a new viral pathogen is discovered, its genome sequence can be used to predict not only if the virus encodes a helicase, but also exactly which helicase family in which the putative helicase belongs. If the properties of that particular family are understood, it is likely that the helicase of interest shares many of the same features.
The evolutionary relationship of all known viral helicases is outlined in Fig. (1) . Based only on protein sequence analysis, Koonin and his colleagues have shown that all helicases can be placed in one of several genetic families [11] . All but two of the helicase families can be grouped into one of three larger "superfamilies, " designated as superfamily 1 (SF1), superfamily 2 (SF2) [12] , and superfamily 3 (SF3) [13] . The remaining 2 families are more similar to the RecA protein and the F 1 ATP synthase than helicases in the three helicase superfamilies. One family is similar to the DnaB helicase of E. coli [14] and the other is similar to the E. coli Rho helicase that is used in transcriptional termination [15] . Of these two "odd" families, only the DnaB-like family contains viral (i.e. bacteriophage) proteins. The DnaB-like helicase family is sometimes called family 4 (F4) [16] , some authors refer to it as superfamily 4 (SF4), and others mistakenly combine the DnaB-like helicases with those in SF3. Sequence analysis reveals the DnaB-like family and the SF3 families are evolutionarily distinct [14] , and as we will see below, the SF3 and DnaB-like helicases appear to function somewhat differently. The various helicase families are distinguished by the presence of specific conserved signature sequences, some of which are conserved in all helicase families, some of which are slightly different between families, and some of which are unique (see reference [16] for a review of these helicase motifs).
Helicases are also classified based on their quaternary structures and their direction of movement. Some helicases oligomerize to form rings (usually hexamers) that appear in electron micrographs to encircle one nucleic acid strand (see reference [17] for a review). Other helicases do not form such rings. All helicases can also be classified according to their movement relative to the nucleic acid strand to which they are primarily associated. In most present models for helicase action, the helicase is depicted as moving along one strand of a double helix while displacing the other strand. Since the strands in a double helix are oriented in an antiparallel configuration, such movement could either occur in a 5'-3' direction or in a 3'-5' direction. The direction of helicase movement can be easily diagnosed by analyzing the ability of a helicase to unwind duplex substrates possessing ssDNA (or ssRNA) tails. 5'-3' helicases only unwind substrates with a 5'-tail, while 3'-5' helicases need a 3'-tail to initiate unwinding. Thus, a helicase can be classified based on each of the three above schemes. For example the helicase encoded by HCV is a SF2, non-ring, 3'-5' RNA helicase. HPV helicase is a SF3, ring, 3'-5' DNA helicase.
KNOWN VIRAL HELICASES AND THEIR PROPER-TIES
Viruses encode helicases that are members of SF1, SF2, SF3, and the DnaB-like family. In Table 1 , the known viral helicases are grouped according to virus genome structure, order, family, and species. Below, key viral helicases are discussed based on their functional similarities rather than their phylogenic relationships. We begin with the DnaB-like helicase family, then discuss SF1 DNA helicases, SF1 RNA helicases, SF2 DNA helicases, SF2 RNA helicases, SF3 DNA helicases, and finally SF3 RNA helicases. The discussion is focused on helicases from model organisms and those encoded by important human pathogens, which are highlighted with subheadings.
Two of the best studied viral helicases are the DnaB-like proteins needed for replication of E. coli phages T7 and T4. These helicases are believed to unwind DNA by encircling one strand while displacing the other. While unwinding the double helix, DnaB-like helicases also coordinate leading and lagging strand DNA synthesis. Replication fork coordination is accomplished by interactions with the primase that synthesizes the RNA oligonucleotides needed to initiate new Okazaki fragments (for a review see reference [18] ).
Phage T4 is still perhaps the best model system to study the replication of large DNA viruses. The 168,930 base pair T4 genome with its approximately 300 genes (of which 62 are essential) encodes analogs of almost all proteins needed for DNA replication [19] . The T4 helicase responsible for coordinating leading and lagging strand replication is the product of T4 gene 41 (gp41). The gene 41 protein forms a hexamer [20] that moves in a 5' to 3' direction along the lagging strand DNA template. The gene 59 protein loads the helicase onto the DNA [21] , and once loaded onto DNA, gp41 forms a tight complex with the T4 gene 61 primase [22] . T4 encodes two additional proteins that have also been shown to possess helicase activity but which are not absolutely essential for viral replication under ideal conditions. Both proteins apparently unwind DNA as monomers not as rings like gp41. One of these is the SF1 helicase Dda [23] , and the second is the SF2 helicase UvsW [24] .
The T7 DNA replication system is simpler than that of T4 in that the primase and helicase are covalently tethered as part of the same polypeptide, which is encoded by phage gene 4. T7 gene 4 encodes two different proteins from two separate in-frame start codons. The larger, 63-kDa gene 4 protein, sometimes called gene 4A protein or gp4A, possesses a zinc finger domain that is missing from the shorter 56-kDa protein, which is also referred to as the 4B protein or gp4B. Both gp4A and gp4B combine to form a hexamer that possesses both helicase and primase activities. The Nterminal portion of the gene 4 protein provides primase function [25] , and the C-terminal portion provides helicase function [26] . The zinc finger domain missing from the 56-kDa gp4B helps guide T7 primase to certain sequences on the lagging strand template where primers are synthesized [27, 28] . As a result, hexamers comprised of only the 56-kDa gene 4 protein lack primase activity but retain helicase activity [29] .
There are no known viruses that infect animals (or plants) that express a helicase in the DnaB-like family. Nevertheless, other viral helicases are functionally similar. For example, as discussed below, the SF3 DNA helicases form rings like those made by the DnaB-like proteins. Similarly, one of the helicases produced by HSV forms a tight complex with that virus' primase and is thought to coordinate activities at the DNA replication fork like the DnaB-like proteins. It is the HSV helicase-primase complex that is the target of the new anti-HSV drug candidates.
Herpes Simplex Virus Type UL5:UL52:UL8 Helicase
There are nine different human herpesviruses (HHV), which can be grouped into three sub-families based on their genome sequence and biological characteristics. The α type includes the herpes simplex viruses HHV-1 and HHV-2, and Varicella zoster virus, which cause oral and genital herpes simplex and chicken pox, respectively. The β group includes human cytomegalovirus (HHV-5), HHV-6A, HHV-6B, and HHV-7, and the γ class includes Epstein-Barr virus (HHV-4) and Karposi's sarcoma associated herpesvirus (HHV-8). Of these, HHV-1 (also called herpes simplex virus-1 (HSV-1)) is the best-characterized. The 152,000 base pair HSV-1 genome encodes the synthesis of all the key proteins required for its replication: an origin binding protein (UL9), a ssDNA binding protein (ICP8), a DNA polymerase (UL30), a polymerase processivity factor (UL42), and a helicase-primase complex consisting of the UL5, UL52, and UL8 proteins (see references [30] and [31] for reviews). Within the HSV helicase-primase complex, the NTPase activity is part of the UL5 protein [32, 33] . The UL52 protein contains the primase active site that is responsible for synthesizing RNA primers on the lagging strand DNA. The UL8 protein does not exhibit any enzymatic activity but serves as a co-factor to stimulate both the helicase and the primase activities. UL8 also facilitates nuclear transport of the helicase-primase complex, and coordinates the helicase and primase activities with those of other HSV proteins involved in DNA replication.
The HSV helicase-primase complex unwinds duplex DNA with a 5'-3' directionality and requires the presence of ICP8 and ATP, indicating that ATP fuels the process of unwinding, and that ssDNA binding proteins assist duplex separation by stabilizing partially unwound products [32, 34] . UL5 possesses all the motifs that are conserved among SF1 proteins, and site-directed mutagenesis of the SF1 helicase motifs leads to a complex that lacks an ability to unwind DNA [35, 36] . When UL52 is separated from UL5, ATP hydrolysis is not stimulated by DNA and the protein no longer unwinds DNA [37] , indicating that UL52 is an integral part of the HSV helicase. Site-directed mutagenesis was later used to confirm that UL52 interacts directly with DNA through a zinc finger domain [38] and that while UL52 mainly contacts the ssDNA tail, UL5 interacts with DNA closer to the replication fork [39] . Thus, UL5 and UL52 work together at the replication fork to unwind the double helix and simultaneously synthesize primers on the lagging strand DNA template.
In addition to the above helicase-primase complex, HSV expresses a second helicase that is a member of SF2, not SF1. UL9 is a 851 amino acid (94-kDa) protein that was originally isolated as a protein that specifically binds the HSV origin of replication [40] . Later, it was found that UL9 unwinds DNA with a 3′ to 5′ directionality beginning at these HSV origins [41] [42] [43] .
T4 Dda is another well-characterized SF1 DNA helicase. Dda was one of the first helicases purified because it can be relatively easily separated from cellular ATPases using chromatography [3] . Dda acts as a monomer [44] and translocates in a 5' to 3' direction [45] . Soon after its discovery, it was noted that Dda allows replication to proceed past a DNA-bound RNA polymerase, suggesting that the Dda helicase unwinds a double helix and can also displace proteins bound to DNA [46] . Recently, a kinetic mechanism for such protein displacement by Dda has been proposed based on measurements of the rate of Dda catalyzed displacement of streptavidin from biotin labeled DNA [47] .
Several SF1 helicases have also been cloned from RNA viruses. Most of the RNA virus SF1 helicases are encoded by plant viruses, few of which have been studied in great detail. A few SF1 helicases from animal RNA viruses have been purified and characterized, but in general, less is known about SF1 RNA helicases than the above SF1 DNA helicases. Some of the helicases in this family are made by pathogenic human viruses, the most noteworthy being the virus that causes SARS.
SARS Coronavirus Helicase
Severe acute respiratory syndrome (SARS) is a lifethreatening form of pneumonia caused by an RNA virus classified in the genus Coronavirus. The finding that the SARS virus is a member of this group was surprising because most other coronaviruses cause only relatively mild respiratory illnesses (i.e. the common cold). The genus Coronavirus is part of family Coronaviridae that, along with the families Arteriviridae and Roniviridae, belongs to the order Nidovirales. Nidovirales contains viruses with the largest known RNA genomes. The (+)ssRNA SARS-CoV genome has about 29,700 ribonucleotides with fourteen open reading frames that encode both structural and replicative proteins [48] . The two largest open reading frames (ORF1a and ORF1b) overlap at the 5′ end of the genome. ORF1a and ORF1b are translated into two large polyproteins (pp): pp1a (~490 kDa) and pp1ab (~790 kDa). The Nterminus of pp1ab is identical to pp1a; the C-terminal half of pp1ab is generated by ribosomal slippage [49, 50] . The SARS-CoV polyproteins are then processed by two viral proteases into mature viral peptides, which include both structural and nonstructural proteins. The helicase is part of nonstructural protein 13 (nsp13), which is processed from the C-terminal portion of pp1ab [51] . SARS-CoV helicase is localized on the endoplasmic reticulum of SARS-CoV infected cells, where RNA replication is likely to take place [52] .
Even though SARS-CoV is an RNA virus with no known DNA stage in its lifecycle, SARS-CoV helicase unwinds both RNA and DNA duplexes in a 5′ to 3 ′ direction. To fuel strand separation, SARS-CoV helicase hydrolyzes ATP or any of the eight canonical NTPs [53] . SARS-CoV helicase also has the ability to cleave the terminal phosphate from a triphosphate moiety linked to the 5′ end of a RNA molecule [52, 54] . Using this RNA 5′-triphosphatase activity (RTPase) activity, SARS-CoV helicase is able to prepare viral RNA to receive a 5′ cap structure. The fact that ATP is a competitive inhibitor of the RTPase reaction catalyzed by SARS helicase suggests that the RNA is hydrolyzed at the same active site used to fuel helicase movement [54] . A similar RTPase that plays a role in CAP formation was also found in the SF1 helicase encoded by bamboo mosaic virus [55] In addition to the SF1 helicase motifs, SARS-CoV nsp13 protein, and its relatives from human coronavirus 229E [56] and equine arteritis virus [57] , all contain a cysteine-rich zinc binding domain located at their N-termini. Zinc binding domains have been found linked to other helicases and they are frequently found in proteins that interact intimately with nucleic acids. For example, both the T7 and HSV helicases have zinc binding domains that help facilitate primer synthesis by their attached primases, and the HCV helicase has a zinc ion bound to its N-terminal protease region. When the zinc binding domain attached to nidovirus helicases is altered using site-directed mutagenesis, the virus displays defective RNA synthesis in infected cells [58] and the helicase is not fully active [59] .
Like the proteins in SF1, SF2 helicases generally do not form rings. SF2 is almost as large as SF1 and likewise contains cellular proteins, and proteins encoded by both DNA and RNA viruses. Many are key proteins for the replication of RNA viruses, and they unwind duplex RNA structures before and/or after RNA genomes are copied by viral RNAdependent RNA polymerases. Other SF2 helicases act during transcription, translation, or to dislodge RNA binding proteins. Several SF2 proteins have been isolated from a variety of viral pathogens; the best studied being the helicase encoded by HCV. Many of the viral RNA helicases in SF2 belong to a large family of evolutionarily related proteins called DExD/H box proteins [60] . This family is named after a shared Asp, Glu, and Asp (or His) containing sequence in the second conserved SF2 helicase motif (see references [61] and [62] for reviews of DExD/H box proteins).
Hepatitis C Virus NS3 Helicase
HCV is the main agent responsible for non-A-non-B viral hepatitis, and the cause of a world-wide epidemic of chronic liver disease. Current treatments using pegylated interferon and ribavirin are costly, produce severe side effects, and eliminate detectable virus in less than 60% of HCV patients. HCV contains a (+)ssRNA genome with one main open reading frame that encodes a long polypeptide about 3000 amino acids long. The genome is translated and the polypeptide is processed into structural and non-structural (NS) proteins by both cellular and viral proteases. While the structural proteins generate the viral capsid and envelope proteins, the NS proteins are responsible for genome replication. RNA synthesis is carried out by the NS5B RNA-dependent RNA polymerase. HCV helicase is part of the bi-functional NS3 protein, which possesses helicase, NTPase, and serine protease activities. The two N-terminal NS3 domains provide protease function, and the remaining three C-terminal domains comprise the helicase activity. The NS3 helicase region was first shown to have RNA stimulated ATPase [63] , and was later shown to bind RNA [64] , unwind RNA [65, 66] and DNA [67, 68] .
There are approximately 12 distinct types of HCV, called genotypes, which have nucleotide sequences that differ by as much as 30%. All of the various HCV genotypes are grouped into the genus Hepacivirus, which is one of three genera in Flaviviridae. The other two genera are Flavivirus and Pestivirus, both of which have a genome organization similar to HCV, with the helicase formed by the C-terminus of the NS3 protein. The Flavivirus genus includes several important pathogens such as the prototype yellow fever virus (YFV), Dengue fever virus (DFV), West Nile virus (WNV), and Japanese encephalitis virus (JEV). The Pestivirus genus contains viruses infecting non-human animals including some that cause serious livestock infections, such as Bovine viral diarrhea virus (BVDV).
Flavivirus Helicases (YFV, JEV, DFV, and WNV Helicases)
The mosquito-born YFV is endemic in sub-Saharan Africa and tropical South America and, although rarely fatal, still poses a threat to unvaccinated travelers. Like YFV, there is a vaccine for JEV, which is the leading cause of viral encephalitis in Asia. Dengue fever, with symptoms that range from mild fever to a fatal hemorrhagic syndrome, is more serious because no vaccine is available. Both yellow and Dengue fever have seen resurgence since mosquito eradication programs have been scaled back. WNV is a bird virus that is also spread to humans by mosquitoes and has recently received much attention since its introduction to North America. WNV normally causes only mild flu-like symptoms but compromised WNV patients may suffer severe neurological damage.
Although the NS3 protein from YFV has not yet been shown to unwind RNA, it does possess RNA stimulated NTPase activity [69] . Many related viruses including DFV [70, 71] , WNV [72] , and JEV [73] have each been shown to unwind RNA in a 3′ to 5′ direction. Although nucleic acid stimulates ATP hydrolysis catalyzed by flavivirus, pestivirus, and hepacivirus helicases, different nucleic acids stimulate the enzymes differently. Each enzyme possesses a distinct nucleic acid stimulation profile, suggesting that they bind RNA (or DNA) in a sequence specific manner or unwind certain sequences better than others [63, 74] . Some flavivirus helicases also contain an additional conserved nine amino acid sequence upstream from the SF2 helicase motif 1 that is not present in HCV NS3 [75] . Called the "Q motif, " this region likely interacts with the adenine base and could explain the ability of certain nucleoside analogs to inhibit flavivirus helicases but not HCV helicase [76] .
The flavivirus NS3 helicases also differ from HCV helicase in that flavivirus helicases possess RTPase activity, as has been shown with both DFV [71, 77] and WNV [78] . Like the SARS-CoV helicase, the flavivirus helicases specifically cleave the β-γ bond of a triphosphate linked to the 5′ end of a RNA in the first step needed to generate a RNA 5′-terminal cap structure [71, 77, 78] . Although the next enzyme in the capping pathway, which transfers a GMP to the RNA 5' diphosphate has not yet been identified, flaviviruses encode a RNA cap methyltransferase (the NS5 protein) that methylates the G 5_ ppp-5_ N RNA cap at the 7 position of guanine [79] . Since HCV utilizes a 5′ internal ribosomal entry site (IRES) instead of cap-dependent RNA translation, its RNA likely lacks the 5′-cap structure present in flavivirus and coronavirus genomes.
DNA viruses also encode members of SF2. As mentioned above, both HSV and phage T4 encode SF2 helicases, the UL9 protein and UvsW proteins, respectively ( Table 1) . In general, SF2 helicases encoded by DNA viruses are not directly involved in coordinating proteins at the DNA replication fork (like the DnaB-like and SF3 helicases). Rather, SF2 proteins from DNA viruses are often found to be involved in DNA repair, recombination, transcription, or translation. Those needed for transcription are most similar to the RNA helicases in the DExD/H-box family. Some of the proteins in this group are required for virus replication, but some are not because host factors can substitute for their functions.
Four different proteins in the SF2 helicase family are encoded by the prototypic poxvirus vaccinia virus [80] . Vaccinia virus (VV) has been the choice model system to study transcription in part because the viral RNA polymerase and numerous transcription factors are packaged into each virion. Vaccinia virus has a linear double-stranded DNA genome of 192,000 base pairs, which it replicates in the cytoplasm. VV genes are assigned letters and numbers based on a restriction map of the virus. The four VV SF2 helicases are the NTP phosphohydrolase I (NPH-I) encoded by gene D11L [81] , NTP phosphohydrolase II (NPH-II) encoded by I8R [82] , the A18R gene product [83] , and the VV early transcription factor (VETF) encoded by D6R [84] . Of the four, NPH-II is the best characterized. As an RNA helicase, NPH-II can unwind duplex RNA in a processive manner [85] , and dislodge RNA binding proteins as it moves in a 3'-5' direction [86, 87] .
Unlike the SF1 and SF2 helicases, SF3 helicases generally form rings like the DnaB-like helicases. SF3 contains many viral proteins. In fact, SF3 contains only viral proteins, which are derived from both DNA and RNA viruses. Although the best studied SF3 helicase is a protein synthesized by SV40, which causes no known disease in humans, SF3 also contains proteins from key human pathogens, such as HPV and poliovirus.
The best studied SF3 helicases are those encoded by small non-enveloped viruses with short, circular doublestranded DNA genomes. These viruses are grouped into the families Polyomaviridae and Papillomaviridae, which until recently were subfamilies in a family called Papovavirdae.
They are now grouped as separate families because their genomes have been found to be clearly different. Polyomaviruses have smaller genomes (~5,000 base pairs), and papillomaviruses have larger genomes (~8,000).
The prototype polyomavirus is simian virus 40 (SV40). SV40 has been intensely studied since it was found contaminating early polio vaccines. SV40 is pathogenic to monkeys, and causes tumors in hamsters, but fortunately seems to cause no ill effects to humans who were inadvertently inoculated with SV40. Related polyomaviruses, such as the JC virus and the BK virus, infect the majority of the world's population causing no apparent harm except to severely immuno-compromised patients, in whom JC virus can cause the fatal neurological disorder progressive multifocal leukoencephalopathy [88, 89] . The small polyomavirus genome encodes only six proteins, which are expressed from either early or late promoters. Three of the four proteins expressed from the late promoter are capsid proteins. The mRNA transcribed from the early promoter is alternatively spliced to yield either small or large T antigens, so named because they can be detected in animals bearing polyomavirus induced tumors. The small t antigen (tag) and large T antigen (Tag) share the same N-terminus, but differ at their C-termini. Tag (79-kDa) is much larger than tag, which is only 20-kDa. Tag assembles as two hexamers that each surround DNA when they binds the SV40 origin of replication [90] [91] [92] . The duel Tag hexamers both move in a 3' to 5' direction [93] with respect to the strand on which they are bound and act to open a replication bubble so that two replication forks can assemble and proceed in opposite directions. In the process, Tag interacts with and coordinates the action of numerous cellular DNA replication proteins (for review see [94] ).
Human Papillomaviruses Helicase
The human papillomaviruses are similar to polyomaviruses except that they have slightly larger capsids and larger, somewhat more complex, genomes. There are over 100 known human papillomaviruses, which are numbered as HPV-1 through HPV-96 (over 20 types are still unclassified). All HPVs infect the epithelial tissues, and the vast majority "low risk" types only lead to benign warts or lesions on the pharynx, esophagus, or genitals. A few "high risk" variants, such as HPV-16, HPV-18, and HPV-31, can cause cervical cancer [95] . The ~8,000 bp small closedcircular double-stranded DNA HPV genome contains several open reading frames that are translated and processed into eight early (E1 to E8) and two late (L1, L2) gene products [96, 97] . L1 and L2 form the viral capsid, and the early gene products are responsible for viral replication. The HPV helicase is the E1 protein (for review see [98] ).
HPV E1 contains a nuclear localization signal at its Nterminus, a site-specific DNA binding domain in the central region, and an SF3 helicase domain within the C-terminal region. While the E1 C-terminal domain alone is sufficient for oligomerization, ATP hydrolysis and DNA unwinding, the entire E1 protein is needed for HPV replication in vivo because the N-terminal domains specifically bind origins. Stable formation of an E1 complex at the HPV DNA origin of replication requires the recruitment of E1 monomers by the HPV E2 protein, which also binds to the HPV DNA origins through its own DNA binding domain [99] . By interacting with E1, E2 loads the E1 helicase on the HPV DNA origin. When E1 and E2 first interact, E2 blocks the E1 oligomerization interface, ensuring the proper assembly of the E1 proteins at the HPV DNA origin [100] . E2 association with the E1-DNA origin complex is then destabilized upon binding of ATP to the E1 protein [100, 101] . The E1 monomers then oligomerize, forming a double hexamer around the DNA substrate [102] . As in the SV40 system, the hexamers move away from each other because they are associated with complementary strands that have opposite polarities, and their movement forms two replication forks at opposite ends of a replication bubble [102] .
SF3 DNA helicases are also encoded by viruses with ssDNA genomes, such as the human parvovirus adenoassociated virus (AAV), a small, apparently harmless virus used for gene therapy [103] . The 4700 nt ssDNA AAV genome has only two open reading frames, one of which encodes four Rep proteins that make a SF3 DNA helicase needed for integration into the human genome. The Rep open reading frame encodes 4 different proteins, called Rep78, Rep68, Rep52, and Rep40, by alternate RNA splicing. All four Rep proteins, including the smallest Rep40, share a central motor domain needed for integration. The largest version, Rep78, forms a hexameric ring when bound to the AAV origin of replication [104] . Rep68 and Rep40 lack a C-terminal zinc finger domain that is present in Rep78 and Rep 52. Rep40 and Rep52 lack the 224-amino acid Nterminal domain common to Rep78 and Rep68. Rep52 retains an ability to unwind DNA in a 3' to 5' direction, but does not apparently need to form rings to catalyze the reaction [105] .
Surprisingly little work has been done with the SF3 helicases encoded by RNA viruses. One might suspect that they are similar to SF3 helicases encoded by the small DNA viruses in form and function, but there is as yet no direct evidence to support this contention. RNA viruses that infect both plants (families Comoviridae and Sequiviridae) and animals (families Picornaviridae and Caliciviridae) have been predicted to encode SF3 helicases but none of the proteins have been shown to unwind duplex RNA. Nevertheless, the poliovirus 2C protein [106, 107] , the polio-like virus echovirus 9 strain barty NS protein 2C [108, 109] , and a Norwalk-like virus 2c-like protein, called p41 [110] have the abilities to hydrolyze NTPs. Perhaps the conserved motor function in these proteins is used for something other than RNA unwinding.
HELICASE STRUCTURE AND FUNCTION
Over 20 different helicases have been studied at an atomic resolution using x-ray crystallography and/or nuclear magnetic resonance (NMR). Six of these helicases are proteins from viruses, and they include two non-ring helicases from HCV and phage T4, and four ring helicases from phage T7, AAV, HPV, and SV40. The structures reveal that even though all helicases share a common fold surrounding the ATP-binding site, ring (DnaB-like and SF3) and non-ring helicases (SF1 and SF2) harness the energy liberated from ATP hydrolysis to unwind DNA differently. ATP hydrolysis by non-ring helicases causes a shift in two domains cova-lently linked on the same polypeptide, while in ring helicases ATP hydrolysis leads to movement of the various subunits in the ring relative to each other. The structures of several SF1, SF2, SF3, and DnaB-like helicases have been reported and the structures within each superfamily appear quite similar. How these structures relate to the function of each class of helicases is discussed below. Correlating structure and function not only clarifies how helicases move along nucleic acids but also facilitates the rational design of helicase inhibitors.
The first viral helicase structures reported were of the HCV RNA helicase (Fig. (2a) ). The first studies utilized recombinant proteins containing only the helicase portion of the HCV NS3 protein, which was isolated from genotype 1a (PDB 1HEI) [111] or genotype 1b (PDB 8OHM) [112] . The HCV genotype 1a NS3 helicase fragment was also crystallized with a bound DNA oligonucleotide (PDB 1A1V) [113] . Later, a crystal structure of the full-length NS3 protein with its NS4 cofactor covalently tethered to the recombinant protein's N-terminus was reported (PDB 1CU1) [114] . The atomic structure of an isolated domain of the 3-domain HCV helicase has also been determined in solution using NMR (PDB 1JR6 and 1ONB) [115] . The structure of another SF2 viral helicase, the UvsW protein from phage T4 (PDB 1RIF), has also been recently reported [24] .
The first ring helicase crystallized was the DnaB-like helicase of phage T7 (Fig. (2b) ). The first studies utilized a short fragment of the T7 gene 4 primase/helicase protein lacking the primase and the linker region connecting the helicase to the primase. Because the linker region is necessary for hexamer formation, this fragment, called the 4E peptide, exists as a monomer in solution and is unable to unwind DNA [26] but crystallized as a filament, which when viewed down the helical axis resembles a six-member ring [116] . Structures are available for the T7 4E peptide alone (PDB 1CR0), with dTTP (PDB 1CR1), with dATP (PDB 1CR2), and with dTDP (PDB 1CR4) [116] . Later, a structure was reported for a larger fragment of the gene 4 protein, called the 4D peptide, that had been previously crystallized [117] . The 4D fragment contains the primase linker, forms hexamers and unwinds DNA. Structures were determined for T7 4D both alone (PDB 1E0K) and with the ATP analog 5'-adenylyl-β−γ-imidodiphosphate (ADPNP) (PDB 1E0J) [118] . Most recently, a structure of the full-length 56-kDa gene 4 protein (4B protein) was reported (PDB 1Q57) [119] .
The three SF3 viral helicases that have been examined using x-ray crystallography all have similar overall folds that are somewhat different from the DnaB-like T7 helicase. The AAV helicase Rep40 has been crystallized without ligands (PDB 1S9H) [120] and as a complex with ADP (PDB 1U0J ) [121] . SV40 Tag (Fig. (2c) ) structure has been determined in the absence of ligands (PDB 1N25 [122] and PDB 1SVO [123] ), with ATP bound (PDB 1SVM) [123] and with ADP bound (PDB 1SVL) [123] . The helicase portion of the HPV E1 protein (residues 428-629) has also been crystallized along with the E2 viral protein, which aids its assembly at the origin (PDB 1TUE) [100] .
All helicase structures share several common features. First, they share a common fold that was first described in the E. coli protein RecA [124] . This "RecA-like" domain consists of a series of beta-sheet sandwiched between two sets of alpha-helices and is so critical to helicase function that all helicases contain at least two such domain. In the non-ring helicases each protein monomer contains two RecA-like domains covalently attached to one another by a short linker (Fig. (2a) ). In ring helicases each subunit of the ring contains one RecA-like domain (Fig. (2b, 2c) ).
The configuration of residues at the ATP-binding site is also similar for all helicases. ATP and a required metal ion cofactor (usually Mg 2+ ) bind to a helicase in the cleft that separates two adjacent RecA-like domains as diagramed in Fig. (3) . The ATP-binding cleft is lined by the conserved residues from the helicase signature sequences. Although the exact composition of the signature sequences varies among the helicase families, all helicases share two amino acid patterns that were first described by John Walker [125] , which are honorably referred to as the Walker A and Walker B motifs. The Walker A motif forms a phosphate binding loop (Ploop) with a conserved Lys that contacts the γ phosphate of ATP. The Walker B motif contains acidic residues that coordinate the positively charged divalent metal cation, which in turn contacts the phosphates of ATP. The ATP-binding site of a helicase is completed by an Arg "finger" and a catalytic base, which accepts a proton from the attacking water molecule. In related proteins this catalytic base has been demonstrated to be a conserved Glu near the Walker B motif [126, 127] . The Arg-finger points from a second RecA-like domain that is adjacent to the domain containing the P-loop and provides a positive charge that stabilizes the transition state [128, 129] . In ring helicases the Arg-finger and P-loop are part of different polypeptide chains in the hexamer [130] , explaining why ring helicases need to oligomerize in order to catalyze a reaction. In non-ring helicases the Arg-finger is part of the C-terminal RecA-like domain while the P-loop is on the N-terminal RecA-like domain.
All theories explaining helicase function suggest that changes in the orientations of the RecA-like domains occur upon ATP binding and hydrolysis, and that these changes subsequently allow the protein to move along a nucleic acid template. The RecA-like domains are thus analogous to a molecular motor and are therefore commonly referred to as "motor" domains. The motor domains move the helicase and any attached cargo along a track of DNA or RNA.
Mechanism of Action of Non-Ring Helicases (SF1, SF2 Helicases)
In addition to contacting ATP, the RecA-like domains in helicases also contact nucleic acids. When the first structures of the HCV helicase were published, the authors speculated that nucleic acid would bind in the cleft that separates the two RecA-like domains [111, 112] . The N-terminal RecAlike domain of HCV helicase (domain 1) contains the P-loop and the C-terminal RecA-like domain (domain 2) contains several conserved arginines that form a basic patch that lines the inter-domain cleft. Although one of these arginines is likely the Arg finger described above (Fig. (3) ), they were at the time believed to form an RNA binding motif. Because the cleft that separates the third HCV helicase domain (domain 3) from domains 1 and 2 is lined with negatively charged residues that should repel RNA, molecular modeling Fig. (2) . Helicase Structures. A. HCV helicase structures [113, 114] . The N-terminal RecA-like domain (domain 1) is colored yellow, the Cterminal RecA-like domain is purple, domain 3 is pink, the protease is green, and the NS3 protease cofactor NS4A is blue. DNA and sulfate ions (which occupy the ATP binding site) are noted as spheres. B. T7 helicase structures [116, 118, 119] . The 4D protein lacks the primase domain of the T7 gene 4B protein (56-kDa gene 4 protein). The 4E protein is like the 4D protein but lacks a linker region necessary for hexamer formation. In the 4D and 4B structures, the different subunits are colored differently. The 4E filament structure is colored based on secondary structure. C. SV40 Tag helicase structures [123] . The different subunits in the SV40 hexamer are noted with different colors. In both B and C nucleotides are displayed as spheres. The noted PDB coordinate files were used to generate the structures using Pymol (DeLano Scientific LLC, San Francisco, CA). logically predicted RNA to bind in the other cleft, the one which separates the RecA-like domains [111, 112] . It was therefore somewhat surprising when a co-structure of a short oligonucleotide bound to HCV helicase showed the DNA bound to the cleft separating domain 3 from the RecA-like domains (Fig (2a) ) [113] . Extensive site-directed mutagenesis of HCV helicase has since confirmed the validity of the HCV helicase-DNA structure and demonstrated that the observed protein-nucleic acid contacts are needed for efficient unwinding [131] [132] [133] [134] [135] [136] . Furthermore, a similar DNA binding cleft, which is perpendicular to the ATP binding cleft, has since been seen in co-structures of two other non-ring SF1 helicases with DNA [137, 138] . Thus, in both SF1 and SF2 helicases, it appears that the single-stranded nucleic acid is bound in a cleft that is perpendicular to the ATP-binding site.
How ATP hydrolysis is translated into helicase movement on nucleic acid is the key question that is presently being addressed in several laboratories. Many of the leading theories propose that movement of the RecA-like domains upon ATP binding and hydrolysis allow the protein to move like an inchworm on one strand, while simultaneously displacing the complementary strand or nucleic acid binding proteins. The most convincing evidence for such a model comes from studies of a non-viral SF1 helicase encoded by Bacillus stearothermophilus called PcrA. PcrA has been crystallized alone [139] , in the presence of an ATP analog [140] , in the presence of DNA, and in the presence of DNA and an ATP analog [138] . These structures show movements of the non-RecA-like domains upon DNA binding, and a closure of the cleft between the RecA-like domains when ATP binds, which coincides with a distortion of the DNA duplex. Based on the rigorous analysis of numerous PcrA site-directed mutants, the interactions seen in the PcrA structures appear mechanistically relevant [141, 142] , and suggest that DNA passes through one end of the helicase when the protein is in the open conformation and the other when it is closed. When ATP is bound, the protein is closed and the cleft opens again after hydrolysis and ADP release. Such movement would permit the protein to move like an inchworm.
The PcrA structures have also provided information about the nature of the forces that move the helicase along DNA. The PcrA-DNA structure differs from that of the PcrA-DNA-NTP structure significantly in the DNA binding site. In both structures, several bases are flipped out of the helix to interact with certain amino acids, but this flipping pattern is different in the two structures. Velenkar et al. propose that sequential ATP hydrolysis events lead to a wave like motion in the side chains that acts to move the protein along ssDNA in a 3' to 5' direction [138] . Soultanas & Wigley call this the "Mexican wave mechanism" because the motion of the side chains is reminiscent of the "waves" that propagate through stadium crowds, which (though common in the USA for decades) were first recognized internationally at the Mexican world cup [143] . This modified inchworm mechanism implies that PcrA helicase would move only one nucleotide for each molecule of ATP hydrolyzed, and this hypothesis is supported by an analysis of the kinetics of oligonucleotide-stimulated PcrA-catalyzed ATP hydrolysis [144] . It is likely that SF1 viral helicases, such as the SARS and HSV helicases, utilize such a method to move on DNA or RNA.
While this wave-like action might work well for non-ring SF1 helicases, SF2 helicases likely function somewhat differently. Although similar inchworm models have been proposed to explain the movement of SF2 helicases, the structure of HCV helicase reveals that the protein makes fewer 
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Asp direct contacts with nucleic acid bases than does PcrA [113] . Instead, most contacts are made with the phosphodiester backbone. The importance of several residues that contact the backbone in the HCV-DNA structure has been verified using site-directed mutagenesis. Critical nucleic acid backbone-binding HCV residues include Thr269 [131] , Thr411 [131] , Thr450 [74] , Arg461 [132] and Arg393 [136] . Only one HCV helicase amino acid side chain, that of Trp501, is known to contact the bases [113] . Trp501 stacks against the base at the 3'-end of the HCV bound oligonucleotide, and is not in a RecA-like domain. Site-directed mutants with an alanine substituted at position 501 unwind RNA poorly [131] [132] [133] [134] [135] . Because it stacks with a base, Trp501 is believed to prevent DNA (or RNA) from sliding through the helicase in the absence of ATP. Kim et al. [113] proposed a "ratcheting" inchworm model suggesting that when ATP binds, the cleft between the RecA-like domains closes, and Trp501 slides past one or two nucleotides. When ATP is hydrolyzed, the cleft opens, and Trp501 acts as a bookend so that the protein moves towards the 5'-end of the nucleic acid. Supporting this model are the observations by Porter et al. that only a few base pairs of fluorescently-labeled DNA are unwound by HCV helicase in a single turnover event and that the helicase binds DNA weaker in the presence of ATP [145] . Others have since confirmed that ATP binding weakens the affinity of HCV helicase for DNA and RNA [136, 146] . However there is yet no general agreement on the number of base pairs unwound in a single event (called "step size"). Levin et al. [147] have calculated a step size of 9 base pairs using unlabeled DNA, and using a long RNA substrate Serebrov & Pyle have determined that 18 base pairs are unwound by HCV helicase in a single step [148] .
Insights into the force which propels the nucleic acid through HCV helicase were recently made when Lam et al. observed that the binding of nucleic acid to a HCV helicase-ATP complex is pH dependent [149] . Thus, electrostatic forces may be as critical for helicase action as the mechanical forces described by the Mexican wave model. Lam et al. proposed that since negatively charged nucleic acid is held in a negatively charged protein cleft, the potential energy buildup could be utilized to propel the helicase along a nucleic acid track. In this "propulsion-by-repulsion" model, ATP binding leads to a conformational change such that the nucleic acid bases can clear the Trp501 bookend. As diagramed in Fig. (4) , in the absence of ATP, RNA cannot exit the enzyme because it is blocked by Trp501 and clamped in the cleft by an Arg "clamp" on domain 2, which has been shown to be critical for binding and translocation [136] . When ATP binds, domain 2 rotates bringing with it the positively charged Arg-clamp. The Arg-clamp attracts the negatively charged phosphodiester backbone so that the RNA moves free from the bookend. The negatively charged RNA is then repelled by the negatively charged binding cleft, so it moves through the protein until ATP is hydrolyzed, and the protein clamps tightly again. Thus, the step size of the protein would depend on the nature of the nucleic acid on which the protein is translocating. For example, since RNA is more polar than DNA, one would predict a larger step size on RNA than DNA as has been observed [147, 148] . Also, a stronger repulsion of RNA would cause the enzyme to fall from that substrate before it would fall from DNA. Such a lower processivity for HCV helicase-catalyzed RNA unwinding than DNA unwinding has been frequently reported [136, 150, 151] .
The above inchworm models all predict that a SF1 or SF2 helicase can function as a monomer but do not account for all observed behaviors of non-ring helicases. For example, with HCV helicase, unwinding rates are not linearly Fig. (4) . The electrostatic inchworm model for HCV helicase movement. In the model, ssRNA is held in a negatively charged cleft separating the RecA-like domains from a third domain. A bookend residue (Trp501 in HCV helicase) prevents ssRNA from sliding through this cleft. Upon ATP binding, the RecA-like domains rotate, moving positively charged RNA-bound residues (e.g. Arg393 in HCV helicase), which in turn move the RNA so that it clears the bookend. Charge repulsion between the RNA and the negatively charged cleft causes the protein to slide along the helix. Based on information from references [136, 149, 236] . dependent on the amount of protein present in the reaction but rather accelerate greatly once a critical protein concentration is reached [136, 151] . Yeast two-hybrid assays also suggest that HCV helicase forms a dimer [152, 153] , and that residues Thr266, Tyr267 and Met288 in domain 1 are critical for dimerization [153] . Kinetic models explaining this cooperativity have recently been presented [147, 154] , and it remains possible that HCV and other non-ring (SF1/2) viral helicases could function as dimers as has been proposed for other helicases like the E. coli Rep [155] and UvrD helicases [156, 157] (for a review of the "rolling dimer" helicase mechanism see [158] ). There is also the possibility that all helicases form rings or filaments on nucleic acid, and we have yet to find the proper conditions to observe these rings with the SF1 and SF2 helicases discussed above. For example, a purified recombinant form of a SF1 helicase encoded by tobacco mosaic virus is capable of forming hexameric rings that can be observed using both gel filtration chromatography and electron microscopy [159] .
Mechanism of Action of Ring Helicases (DnaB-like, SF3 Helicases)
ATP binding and the mechanism of its hydrolysis by ring helicases is basically identical to that outlined above for nonring helicases (Fig. (3) ). The main difference between ring and non-ring helicases is that the Arg finger is on a separate polypeptide chain. Since in ring helicases, there is only one RecA-like domain, each subunit has both a P-loop and an Arg-finger. The subunits are arranged in a head to tail manner, with the head being the P-loop, and the Arg-finger being the tail. The ATP is bound between the head and tail, and there is the same number of binding sites as there are subunits in the oligomer (Figs. (2) and (5)). Even though there can be up to six ATP molecules bound per hexameric helicase ring, fewer sites are often observed. The DnaB-like helicases, like the F 1 ATPase, bind ATP with negative cooperativity. This means that the binding of the first ligands cause a decrease in the affinity for subsequent ligands. As a result, only 2-4 NTPs bind per hexamer [160] . The kinetics of NTP hydrolysis catalyzed by T7 helicase are also remarkably similar to those seen with F 1 ATPase [161] . In both proteins, it appears that ATP is hydrolyzed sequentially by different subunits. In the case of the F 1 ATPase, this leads to a rotation of the γ subunit, which in turn contacts the membrane embedded F o proton channel [162] . When protons pass through the F o complex, the reverse rotation leads to ATP synthesis [163] . In the T7 helicase, the DNA is proposed to be analogous to the γ subunit of F 1 ATPase, and the rotation leads to the helix moving through the oligomer.
The above "rotational" model predicts that one or both strands of DNA pass through the center of the hexamer, as diagramed in Fig. (5) . Although ring helicases have not yet been crystallized in the presence of DNA, this notion is supported by electron micrographs and model building. In the presence of DNA, extra density appears in the central channels of hexamers formed by both T7 helicase [164] and SV40 Tag [165] . Also, electrostatic analysis of hexameric helicase structures reveals in all cases that the central holes are lined with positive charges [116, 118, 120, 122, 123] , which would attract negatively charged DNA. In crystal structures of the T7 helicase portion of the gene 4 protein (Fig. (2b) ) the channel is only large enough to accommodate one DNA strand, suggesting that the other must wind outside the ring as shown in Fig. (5a) [118] .
If DNA does, in fact, pass through the center of T7 helicase, it would make contact with loops that contain residues that were previously shown using mutagenesis to be involved in DNA binding, like Arg487 [166, 167] . These residues are part of the loops that extend from the RecA-like domains into the central channel. The DNA would therefore be perpendicular to the ATP binding cleft, but at an angle somewhat different from that seen in the SF1 and SF2 helicase structures. It is also interesting to note that the subunits of the T7 helicase do not form a symmetrical hexamer. Rather, each subunit of each half hexamer is rotated 15º relative to each other. This means that each DNA binding loop is also rotated relative to the loops in adjacent subunits (Fig. (5c) ). Singleton et al. [118] have proposed that this subunit rotation is modulated by the binding and hydrolysis of ATP. Thus, as the binding loops make sequential contacts with the DNA backbone, they rotate and push the ssDNA through the hexamer. In support of this model, when NTPs are added to T7 helicase crystals, not all the potential sites are occupied, and the side chain configurations are different surrounding each of the three binding site types seen in the asymmetric hexamer [118] .
The ring structure of SF3 and DnaB-like helicases raises the question of how ring helicases are loaded onto DNA to initiate unwinding. In vitro, ring helicases require a forked molecule with ssDNA tails to initiate unwinding, but in vivo, unwinding begins within a duplex at replication origins. Some viruses express AAA+ proteins that use ATP to load the helicase onto DNA. An example is the gene 59 protein of T4 [21] . Other helicases, like T7 helicase, appear to be able to break open the ring to bind DNA. For example, not all crystal structures show the T7 helicase as a ring. In the first structure the subunits packed like a filament (Fig. (2b) ) [116] , and such a filament could be the conformation used by the protein to slip on an off DNA.
In the latest structure of the full length T7 gene 4 protein, the protein is seen as a seven subunit ring instead of a hexamer (Fig. (2b) ) [119] . In the T7 heptamer structure the central channel is large enough to accommodate a duplex. A similar large channel has been reported in SV40 Tag structures (Fig. (2c) ) [122, 123] . A larger channel suggests that a double helix could pass through the protein, and such an arrangement is diagramed for Tag in Fig (5b) . SV40 Tag was recently crystallized alone, with ADP, and with ATP with interesting results that support a fundamentally different model for translocation than the rotational model describing T7 helicase action. First, all six potential SV40 Tag NTP binding sites bind nucleotides. This evidence would support the more traditional Monod-Wyman-Changeux "concerted" model of ligand binding [168] . Second, upon NTP binding, changes in subunit rotation create an "iris-like" motion so that the diameter of the channel changes and six β hairpins, suspected to bind DNA, change orientation within the channel. The motion of the hairpins could push DNA through the center of the protein as has been proposed with T7 helicase, but all binding loops move together rather than in pairs. Thus, SF3 helicases could be fundamentally different from DnaB-like helicases in that ATP hydrolysis occurs via a concerted rather than a sequential mechanism. Both the sequential model (Fig. (5a) ) and concerted model (Fig. (5b) ) predict that DNA movements are controlled by a binding loop (or hairpin) in the center of the ring that remains connected to the same point on the DNA backbone during a single cycle of ATP binding and hydrolysis. As diagramed in Fig. (5c) , as the hairpin moves, so does the protein relative to the DNA. Fig. (5) . The sequential and concerted models for ring helicase action. A. In the sequential "rotational" model for T7 helicase movement, the various subunits hydrolyze ATP in turn to cause the protein to rotate along one strand of DNA while displacing the complementary strand [118] . B. In the concerted model for SV40 helicase action, all subunits simultaneously bind and hydrolyze ATP [123] . C. Both models predict that ATP hydrolysis leads to a rotation of DNA binding loops that contact DNA in the center of the hexamer. If the binding loops remain attached to the same point on DNA during an entire ATP hydrolysis cycle, then the protein will move along DNA as diagramed.
Outside the RecA-like domains helicase structures differ considerably. The non-RecA-like domains act to confer unique properties to the helicase, which might involve additional nucleic acid binding motifs, or motifs needed to interact with other proteins. Helicases are usually intimately associated with other proteins that travel with them along a nucleic acid chain. Many helicases form a tight complex with one or more other proteins and sometime the helicase is covalently tethered to a separate independent functional domain with an entirely different biological activity. For example in many RNA viruses, including HCV and SARS-CoV, the helicase is part of a protein that also possesses a protease function (Fig. (2a) ). No relationship between helicase and protease has been clearly defined, but the helicase might, for example, allow the protease to travel with cellular translation machinery to help coordinate viral polyprotein processing. In a similar example, helicases that coordinate semi-discontinuous DNA replication, such as T7 and HSV helicases, are found coupled to a primase that synthesizes primers on the lagging strand (Fig. (2b) ).
POTENTIAL ANTIVIRAL AGENTS

SF1 Helicase Inhibitors
In addition to the HSV helicase-primase inhibitors that are being developed as antiviral drugs [1, 2] , inhibitors of other SF1 RNA helicases such as the SARS-CoV helicase, have been reported [169] . Both classes of compounds could serve as templates to develop inhibitors of any SF1 helicase (Fig. (6) ).
Current HSV therapies using nucleoside analogs such as acyclovir are quite effective but frequently lead to the evolution of resistant viruses. Since chain terminating nucleoside analogs must be activated before incorporation by HSV polymerase, the virus can develop resistance by not expressing a functional kinase or by evolving a polymerase with a higher fidelity. Because the new helicase-primase inhibitors do not require metabolic activation, the virus has fewer pathways through which it can develop resistance. The new series of HSV helicase-primase inhibitors, currently in preclinical development at Boehringer Ingelheim [1] and Bayer [2] , offer a new option for treating acyclovir-resistant infections, and appear more effective than current drugs for treating latent HSV infections. Representatives of the two series of compounds are shown in Fig. (6a) . The Boehringer Ingelheim series (e.g. BILS 179 BS) was first identified by screening inhibitors of DNA unwinding, while the Bayer series (e.g. BAY 57-1293) was discovered using a cell-based viral replication assay.
The aminothiazolylphenyl compound BILS 179 BS was identified at Boehringer Ingelheim as a HSV UL5/UL52/ UL8 inhibitor using a high throughput helicase assay [1] . A later derivative called BILS 45 BS, which is absorbed more rapidly into the blood, differs only by the lack of a methyl group [170] . In the presence of the inhibitor, HSV primase activity is inhibited with an IC 50 of 0.15 µM, while the DNA unwinding activity of the HSV helicase is inhibited with an IC 50 of 1.3 µM. BILS 179 BS also inhibits DNA-stimulated ATP hydrolysis (IC 50 ~0.43 µM) but does not affect the ATP hydrolysis in the absence of DNA (IC 50 >100 µM). DNA binds more tightly to an UL5/UL52/UL8 complex in the presence of BILS 179 BS. Thus, BILS 179 BS likely inhibits HSV helicase-primase activity by preventing DNA release during translocation [1] .
As measured by plaque formation, BILS 179 BS decreases HSV DNA replication in BHK cells infected with either wild type HSV strains or acyclovir-resistant mutants (EC 50 ~100 nM). HSV infected mice fed BILS 179 BS, or its derivative BILS 45 BS, have fewer and smaller cutaneous and genital lesions than mice fed a placebo. HSV viral titers also show a dose dependent reduction following administration of the BILS compounds [1, 170] . Mice infected with acyclovir-resistant HSV also respond to oral administration of BILS 45 BS [170] . Thus, these aminothiazolphenyl-based molecules are a promising class of compounds for the treatment of nucleoside-resistant HSV disease in humans.
In order to determine which protein component of the HSV helicase-primase complex is targeted by the BILS compounds, HSV was incubated with cells in the presence of BILS 22 BS (an analog of BILS 45 BS). Three mutant viruses were found to have mutations in their UL5 gene [171] . One had Gly352 changed to Val, one had Gly352 changed to Cys, and the third had Lys356 changed to Asn, indicating that the UL5 subunit of the HSV helicase-primase is likely the target of the BILS inhibitors. Gly352 and Lys356 are near SF1 conserved motif IV, with Gly352 only 2 amino acids downstream from SF1 motif IV. DNA-stimulated ATP hydrolysis catalyzed by purified UL5/UL52/UL8 complexes with these mutations is less sensitive to the inhibitors. Both Gly352 and Lys356 are completely conserved in all human herpesviruses [172] , but the mutant viruses are viable and still cause disease [171] . The frequency with which BILS resistant mutants arise is significantly less than that seen for acyclovir-resistant mutants [171] .
Unlike the Boehringer Ingelheim compounds, which were identified using high throughput enzyme assays, the development of BAY 57-1293 (Fig. (6a) ), was initiated using a cell-based high throughput assay [2] . In this assay, which measures HSV induced cytopathogenicity, BAY 57-1293 (IC 50 = 20 nM) is 50-fold more potent than acyclovir (IC 50 = 1 µM). In addition, BAY 57-1293 inhibits acyclovirresistant HSV-induced cell lysis with the same potency as wild type HSV-induced cell damage.
The first indication that the HSV helicase-primase was the target for the BAY compounds came when resistant mutants were sequenced. Seven amino acid substitutions were identified, six of them clustered near the N-terminal of the UL5 gene and one mutant had a substitution in the UL52 gene [2] . As with the BILS compounds, BAY 57-1293-resistant mutants contain mutations (G352V, M355T, K356Q) near SF1 motif IV. Remarkably, two of these are at the same positions as the BILS-resistant mutants. All three positions are completely conserved in all human herpesviruses. BAY 57-1293 resistance occurs about 10 times less frequently than acyclovir resistance [2] .
Biochemical assays using purified HSV helicase-primase also show that BAY 57-1293 inhibits the DNA-stimulated ATPase activity in a dose-dependent manner with an IC 50 of 30 nM. Orally administered BAY 57-1293 has potent antiviral efficiency in mice, rats and guinea pigs infected with HSV-1 or HSV-2. BAY 57-1293 is 40 times more effective than acyclovir in treating mice infected with cutaneous HSV-1, suppresses intravaginal lesions in HSV-2 infected guinea pigs, and exhibits a potent antiviral effect in rats infected with HSV-1 [2, 173] . In addition, BAY 57-1293 reduces healing time and is effective even when treatment is delayed, as opposed to the nucleoside analogs which require early application upon HSV infection [2] .
A cell-based assay similar to that used to discover the BAY series of HSV helicase inhibitors was also used to find compounds that inhibit cell death induced by SARS-CoV. Kao et al. found 104 compounds that protect cells from SARS-CoV induced cytopathic effects [169] . Of these, seven were potent inhibitors of recombinant purified SARS-CoV helicase-catalyzed DNA unwinding and ATP hydrolysis. The structure of one, which also suppresses viral plaque formation in SARS-infected tissue culture cells with an EC 50 of 6 µM, is shown in Fig. (6b) ). HE602 inhibits nucleic acidstimulated ATP hydrolysis by SARS-CoV helicase with an IC 50 of 6.9 µM, but has no effect on its basal rate of ATP hydrolysis. Fig. (6) . SF1 helicase Inhibitors. A. HSV helicase-primase inhibitors [1, 173] . B. SARS-CoV helicase inhibitor [169] .
SF2 Helicase Inhibitors
Numerous compounds have been reported that inhibit the HCV, WNV, and JEV helicases. These inhibitors can be classified into three basic groups: (1) nucleoside analogs and related small molecules that modulate ATP hydrolysis and/or nucleic acid unwinding, (2) nucleic acids and modified derivatives that specifically target the RNA-binding site, and (3) antibodies.
Small molecule inhibitors of HCV helicase and related helicases were recently reviewed by Borowski and his colleagues in references [174] and [175] . One of the most (Fig. (7) ), which inhibits WNV helicase and produces a potent antiviral effect (IC 50 = 25-30 µM) in WNV-infected cells [176] . Interestingly, a lower concentration of HMC-HO4 is needed to inhibit viral RNA synthesis in cells than is needed to inhibit DNA (and presumably RNA) unwinding by purified WNV helicase. At the lower HMC-HO4 concentrations that produce an antiviral effect (i.e. below 20 µM), DNA unwinding rates catalyzed by the purified enzyme are actually stimulated. At higher HMC-HO4 concentrations, unwinding is inhibited as is viral RNA synthesis. At all concentrations of HMC-HO4, ATP hydrolysis is stimulated, suggesting that the inhibitor somehow uncouples the ATPase and helicase functions [176] .
Another explanation for the effect of HMC-HO4 on WNV helicase is that the compound binds to a second NTP binding site other than the one made by the cleft between the RecA-like domains. Some evidence for such a site has come from studies of the related HCV helicase. The HCV helicase hydrolyzes all eight canonical nucleoside triphosphates [74, 177, 178] , but some reports suggest that not all NTPs fuel equal rates of unwinding. For example, Locatelli et al. found that only some NTPs fuel unwinding with an efficiency comparable to that seen with ATP whereas other (d)NTPs, particularly dATP, were found to be poor substrates and potent inhibitors of unwinding [179] . Although other studies have not confirmed their observations [178, 180] , Locatelli et al.'s report [179] suggests that NTPs could bind at two sites, one used to fuel helicase movement, and a second that allosterically modulates the enzyme's activity.
Other evidence for a second site arises from product inhibition studies. The products of ATP hydrolysis, ADP and P i , do not inhibit the HCV NS3 helicase. However, in the presence of NaF and PolyU RNA, ADP inhibits ATP hydrolysis with about two moles of ADP binding per protein monomer [181] . When beryllium fluoride is added to the reaction, ADP inhibits ATP hydrolysis more potently with a K i of about 8.5 µM [136, 146] . In structures of other enzymes, BeF 3 is often found to occupy a position analogous to the γ phosphate of ATP when bound with ADP and Mg 2+ [182] . Thus, ADP(BeF 3 ) is likely a non-hydrolyzable ATP analog, but unlike other non-hydrolyzable ATP analogs such as ADPNP [177, 183] , ADP(BeF 3 ) binds HCV helicase tightly. ADP(BeF 3 ) binds with a stoichiometry of one nucleotide per protein monomer and mimics ATP in that it reduces the affinity of the helicase for nucleic acids in the same manner as ATP [136, 146, 149, 184] . ADP(BeF 3 ) also binds other P-loop ATPases as a ground state ATP analog [182] , explaining the cellular toxicity of beryllium fluoride. ADP fluoride complexes, on the other hand, likely do not resemble the substrate as closely, so they may bind both active and allosteric sites. Other evidence of a second ATP binding site was presented in a second report by Locatelli et al. that demonstrated that nucleotides bind HCV helicase cooperatively [185] .
Thus, it is possible that the interaction between HCV helicase and nucleotides could be effectively exploited for drug design by finding compounds that bind the second putative binding site. Such compounds would not competitively inhibit ATP hydrolysis, but would modulate ATP hydrolysis and/or unwinding by binding an allosteric site. Several such compounds recently have been reported [186] [187] [188] . Representatives are shown along with HMC-HO4 in Fig. (7) .
A series of halogenated benzimidazoles and benzotriazoles, which were originally reported as HCV inhibitors in patents by Viropharma Inc., were recently examined for their ability to inhibit HCV, WNV, and JEV helicases [186] . Dichloro(ribofuranosyl)benzotriazole (DRBT) and dichloro(ribofuranosyl)benzimidazole (DRB) are nucleoside analogs, while tetrachlorobenzotriazole (TCBT) and tetrabromobenzotriazole (TBBT) are base analogs. DRBT, DRB, TCBT, and TBBT inhibit WNV helicase catalyzed RNA unwinding with IC 50 's in the low micromolar range, but only TBBT (Fig. (7) ) inhibits RNA unwinding by HCV NS3 helicase (IC 50 ~60 µM). Interestingly, none of these inhibit the JEV helicase, even though it is closely related to WNV helicase. Under the conditions used, none of the compounds inhibited helicase-catalyzed ATP hydrolysis, suggesting that they may bind to another NTP-binding site or interact with the nucleic acid substrates [186] . [176] . B. Halogenated benzotriazole inhibitor of WNV helicase and HCV helicase [186] . C. Ringexpanded nucleoside inhibitor of WNV helicase [187] .
Several ring-expanded "fat" nucleosides (RENs), which are currently being investigated as antiviral and anticancer agents (see ref. [189] for a review), have also recently been examined as potential inhibitors of the WNV, JEV, and HCV helicases [187, 188] . At least five different RENs inhibit WNV, one inhibits JEV, but none inhibit HCV helicase catalyzed DNA or RNA unwinding. Many of the RENs, such as compound 17 (Fig. (7) ), are more potent inhibitors of either WNV helicase-catalyzed RNA or DNA unwinding, suggesting that they exert their effects by binding the major or minor groove of the duplex nucleic acid. Only one REN was found to inhibit both DNA and RNA unwinding by WNV helicase. Again, as seen with HMC-HO4 and TBBT, inhibition of the unwinding activity by RENs does not correlate with a reduction in ATP hydrolysis (unless REN triphosphates are used in the assays). To see any inhibition of ATP hydrolysis ATP must be used at a concentration well below its apparent K m , and under such conditions only two RENs show any inhibition. At high concentrations (> 0.5 mM), all of the RENs enhanced ATP hydrolysis. None of the RENs were reportedly tested in cell-based assays for a true antiviral effect although antiviral effects for RENs have been reported for other viruses [189] .
Another method to inhibit a helicase is to directly target the nucleic acid-binding site rather than the NTP-binding site. The HCV NS3 helicase nucleic acid-binding site is located in the cleft that separates domains 1 and 2 from domain 3 (Fig. (2) ), and represents a target site for antiviral drugs that compete with HCV helicase for its viral RNA substrate.
SELEX (systematic evolution of ligands by exponential amplification) has been used to find RNA sequences that tightly bind HCV helicase. Such sequences, called "aptamers, " are oligonucleotides that exhibit molecular recognition, and could conceivably be directly used as antivirals, or could provide templates for the synthesis of antiviral drugs. In the SELEX procedure (see [190] for a review), an RNA library is screened for sequences that bind a macromolecule using a binding assay. Only those sequences that bind tightly are amplified to create a new library, and the selection process is repeated with the new library. Nishikawa's group first used SELEX to uncover a series of aptamers with specific affinity to the NS3 protease region. The protease-binding aptamers all share the conserved sequence GA(A/U)UGGGAC [191] . These aptamers bind to the NS3 protease with high affinity (K d ~10 nM) and are effective at inhibiting the HCV NS3 protease [191, 192] . The conserved part of the RNA aptamers likely interacts with a cluster of basic amino acid (residues Arg130, Arg161 and Lys165), which is located outside of the serine protease catalytic pocket in the region that links the protease to the helicase [193] . When a 14-mer uridine tail is added to one of the most effective HCV protease-binding RNA aptamers, the new, longer aptamer interacts with both the protease and helicase domains of the full-length NS3 protein [194] . This dual-function RNA aptamer binds to the HCV NS3 helicase domain with high affinity (K d ~4 nM) [194] and also inhibits the NS3 helicase activity with an EC 50 of ~500 nM.
An aptamer that bind HCV helicase have also been directly selected using the helicase domain of the NS3 protein as the bait in the SELEX procedure [195] . This aptamer (called SE RNA) folds to form four stem loops with GC pairs that are similar to the stem loop located at the 3'-terminal of the negative strand HCV RNA. Since previous studies have shown that HCV helicase specifically binds to this region of the HCV genome [196] , the SE aptamer might compete for this binding site. SE RNA binds the HCV helicase with a high affinity (K d ~990 pM), efficiently competes with poly(U), stimulates ATP hydrolysis, but severely inhibits RNA unwinding (IC 50 ~12.5 nM). Most importantly, human liver cells (Huh 7) infected with HCV replicons show less HCV RNA synthesis in the presence of SE RNA.
Although directly using RNA as an antiviral drug will be challenging because of its cellular instability, the information derived from aptamer studies could be used to make more stable derivatives. For example, the same aptamer sequences could be used to generate peptide nucleic acids (PNA), which are modified nucleic acids composed of natural purine and pyrimidine bases linked together via an uncharged 2-aminoethyl-glycine backbone. Both HCV helicase [197] and HSV UL9 helicase [198] have been shown to be inhibited by PNA. PNA most likely inhibits helicase activity by forming a duplex that is more stable than those seen with natural DNA or RNA: The PNA-DNA substrates are unwound more slowly (up to 80-fold) when compared to DNA duplexes containing the same sequence, and only minimal PNA-RNA duplex is unwound by the HCV NS3 helicase [197] .
Delivery of RNA aptamers to infected cells also presents a challenging problem. One logical way to introduce an aptamer is to introduce a gene, encoding its transcription, into cells using an appropriate vector. Using such a gene therapy approach, the aptamer would be expressed inside cells (for review see [199] ).
Gene therapy can also be used to introduce protein molecules into cells. The most practical proteins to introduce are antibodies, which could conceivably act inside a cell to inhibit any enzyme. Antibodies are the first line of defense that the body has against viruses, and have long been recognized as powerful antiviral agents. Natural biological diversity allows for the selection of antibodies that tightly bind virtually any epitope of any enzyme. Once antibodies are isolated with a high avidity for a desired antigen, a gene encoding that antibody can be cloned and introduced into infected cells. This process, called "cellular immunization, " has been used successfully with HIV [200] , and such an approach has been used to target the HCV helicase [201] [202] [203] .
The first anti-HCV helicase antibodies designed for intracellular immunization were single chain fragment (ScF) antibodies. A ScF is composed of the immunoglobulin variable domains, of both the heavy and light chains, connected by a polypeptide linker, and can be constructed using PCR. Several high affinity ScFs that specifically interact with HCV NS3 helicase have been cloned [201, 204] and shown to inhibit HCV helicase catalyzed DNA unwinding [202, 204] . One ScF has been expressed in HCV infected hepatocytes and shown to reduce HCV RNA synthesis [204] . This particular ScF consists of the variable regions of the human monoclonal antibody CM3.B6, which recognizes an epitope that spans conserved SF2 motifs IV and V of the NS3 helicase [205] . Immunoblots show that an intracellularly expressed ScF derived from CM3.B6 interacts with the HCV NS3 protein, and HCV RNA synthesis within primary hepatocytes infected with HCV is reduced by 10-fold when the cells contain an adenoviral vector carrying the ScF gene [204] .
Another approach to achieve intracellular immunization uses an antibody fragment (Fab). A Fab is larger and usually more stable than a ScF because in addition to regions present in ScFs, it contains the complete light chain and the first constant domain of the heavy chain. Prabhu et al. has isolated a human Fab, termed HFab-aNS3, with effective HCV antiviral activity [203] . Derived from a HCV-infected pa-tient, HFab-aNS3 binds HCV helicase and recognizes an epitope that spans motifs I to V of the protein. HCV NS3 helicase pre-incubated with the HFab-aNS3 fails to unwind DNA duplexes. Intracellular expression of HFab-aNS3 within replicon-transfected Huh 7 cells suppresses NS3 protein expression and significantly inhibits positive strand HCV RNA synthesis of both subgenomic and full-length HCV replicons [203] .
SF3 Helicase Inhibitors
Among the viral helicases from SF3, the E1 helicase from HPV is currently the target of antiviral molecules for the treatment of HPV infection. Through screening a compound library, two classes of small molecules have been identified and are being developed at Boehringer Ingelheim. The first group involves agents that disrupt the interaction between the HPV E1 helicase and its co-activator HPV E2 protein. Because HPV DNA replication is dependent on proper assembly of E1 proteins at the HPV origin of replication, which requires initial complex formation between E1 and E2, compounds that interrupt this interaction can potentially serve as promising antiviral drugs. The second group consists of inhibitors that specifically target HPV E1 helicase DNA unwinding.
Using a high throughput assay that analyzes the binding between E1 and E2 proteins, a class of small molecules (HPV E1-E2 inhibitors 1 to 3) that disrupt the E1-E2 complex has been identified [206] . The most potent, inhibitor 3, is shown in Fig. (8) . These inhibitors do not significantly affect E1 helicase activity, nor do they block DNA binding to either E1 or E2. These molecules only target the E2 protein [206] . These molecules bind to the region of E2 that interacts with E1 and prevent it from associating with the E1 helicase. In Chinese hamster ovary cells transfected with plasmids expressing HPV E1 and E2 together with a plasmid containing the HPV DNA origin of replication, HPV DNA replication is inhibited in a dose-dependent manner in the presence of inhibitor 3 (EC 50 ~1 µM). Currently, this class of inhibitors is effective against low risk HPV (types 6 and 11), but unfortunately not the high risk types.
Inhibitors that are specific for the E1 helicase are also being developed [207] . High throughput screening of a library of compounds has identified a lead molecule bearing a biphenyl-4-sulfonylacetic acid moiety, which specifically inhibits the ATPase activity of the HPV-6 E1 helicase. Among the derivatives of this parent molecule, compound 6g demonstrates potent inhibition against the ATPase activity of the E1 protein (IC 50 ~4.3 nM) (Fig. (8b) ). However, it has limited in vivo application because of poor cell permeability and is relatively unstable. These compounds are currently being improved in their chemical structures so they can be suitable for further cell-based evaluation [207] .
CONCLUSION
All viral helicases can be classified as DnaB-like, SF1, SF2, or SF3 helicases. All helicases share a common mechanism of ATP hydrolysis to produce conformational changes allowing the protein to move on DNA (or RNA). Although precisely how chemical energy is converted to mechanical movements is unknown at this time, there is solid evidence that DnaB-like and SF3 helicases encircle DNA as rings. ATP binding to ring helicases causes the movement of loops implicated in DNA binding that could push the protein either by moving in a sequential or concerted manner. The active sites appear to work in concert in SF3 helicases, and sequentially in DnaB-like helicases. There is little evidence that SF1 and SF2 helicases function as rings. Rather, most evidence points to an inchworm mechanism in which the functional unit is a monomer. In non-ring helicases, ATP binds at an interface between two RecA-like domains in a cleft that closes upon ATP binding. The main difference between SF1 and SF2 proteins appears to be that the SF1 helicases move by interacting with the nucleic acid bases whereas SF2 proteins interact primarily with the phosphodiester backbone. Fig. (8) . SF3 helicase inhibitors. A. HPV E1-E2 complex inhibitor [206] . B. HPV E1 inhibitor [207] .
Potent inhibitors have been isolated for members of each superfamily of viral helicases. The best characterized are those that inhibit the SF1 HSV helicase-primase complex. The anti-HSV compounds function by binding near conserved SF1 motif IV, preventing dissociation of the protein from viral DNA, slowing helicase movement, and consequently the activity of the associated primase necessary for viral genome synthesis. The inhibitors of HCV helicase and related SF2 proteins that have been isolated are small molecules, RNA aptamers, or antibodies. Developing the HCV inhibitors will likely be slow but several helicase inhibitors have shown clear efficacy in treating West Nile virus infection. SF3 helicase inhibitors targeting HPV also have been isolated and work by either directly reducing HPV helicasecatalyzed ATP hydrolysis or its interaction with a protein that loads the helicase on replication origins.
Clearly, helicase inhibitors are in an early stage of development and much more work will need to be done until these compounds will be regularly used as antiviral agents. Nevertheless, the critical first steps have been taken, and if new insights into helicase mechanisms continue at the current 
